A Cochrane review included 5 studies with a total of 1 056 subjects. Four trials (895 patients) were included in the analysis of overall survival. Patients treated with rituximab as maintenance therapy had a significantly better overall survival compared to observation alone (HR 0.53, 95% CI 0.38 to 0.73).
Comment: The evidence is downgraded by by study quality (inadequate or unclear allocation concealment and blinding).